Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

IMNMBullishIndustry Newsnews

High materiality8/10

Immunome Doses First Patient in IM-3050 FAP Radioligand Phase 1

Jul 20, 2026, 7:36 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

A Phase 1 dosing milestone for IM-3050 provides a visible near-term catalyst. Positive safety/dosimetry signals or early activity could lift IMNM shares; however, results are data-dependent and early-stage, constraining upside.

AI summary

What happened, with direct paths to the underlying reporting

Immunome announced the first patient has been dosed in the Phase 1 trial of IM-3050, a Lu-177 radioligand therapy targeting FAP in advanced solid tumors. The open-label, multicenter study will evaluate safety, dosimetry, PK, and preliminary anti-tumor activity, with dose escalation to identify a recommended expansion dose. This milestone provides a near-term clinical catalyst for IMNM as data emerge.

IM-3050 is a FAP-targeted Lu-177 radioligand therapy.
First patient dosed in IM-3050 Phase 1 open-label trial.
FAP expressed in ~75% of solid tumors suggests broad potential.
Phase 1 aims to assess safety, dosimetry, PK, and preliminary activity.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Immunome Doses First Patient in IM-3050 FAP Radioligand Phase 1

Immunome's experimental drug meets main goal in late-stage study

Immunome, Inc. (IMNM) Reports Q1 Loss, Misses Revenue Estimates